NASDAQ:AXNX Axonics (AXNX) Stock Price, News & Analysis → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free AXNX Stock Alerts $67.33 -0.10 (-0.15%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$67.20▼$67.6550-Day Range$66.47▼$69.6552-Week Range$47.59▼$69.68Volume318,963 shsAverage Volume1.15 million shsMarket Capitalization$3.44 billionP/E RatioN/ADividend YieldN/APrice Target$70.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Axonics alerts: Email Address Axonics MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside5.0% Upside$70.73 Price TargetShort InterestHealthy6.68% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment1.11Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth159.26%From $0.27 to $0.70 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.55 out of 5 starsMedical Sector280th out of 925 stocksSurgical & Medical Instruments Industry35th out of 100 stocks 1.2 Analyst's Opinion Consensus RatingAxonics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 5 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageAxonics has only been the subject of 2 research reports in the past 90 days.Read more about Axonics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.68% of the outstanding shares of Axonics have been sold short.Short Interest Ratio / Days to CoverAxonics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Axonics has recently decreased by 15.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxonics does not currently pay a dividend.Dividend GrowthAxonics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxonics has received a 59.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Incontinence medication", "Implants and prostheses", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Axonics is -1.38. Previous Next 3.9 News and Social Media Coverage News SentimentAxonics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Axonics this week, compared to 3 articles on an average week.Search Interest1 people have searched for AXNX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Axonics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axonics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.85% of the stock of Axonics is held by insiders.Percentage Held by Institutions99.48% of the stock of Axonics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Axonics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Axonics are expected to grow by 159.26% in the coming year, from $0.27 to $0.70 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axonics is -210.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axonics is -210.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxonics has a P/B Ratio of 5.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Axonics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceYour Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.Click to watch this device in action About Axonics Stock (NASDAQ:AXNX)Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Read More AXNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXNX Stock News HeadlinesMay 3, 2024 | marketbeat.comBoston Scientific Bucks the Medtech Slow Down and Raises Outlook (AXNX)Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook.May 8, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates Hold Rating for Axonics (NASDAQ:AXNX)May 1, 2024 | markets.businessinsider.comWhat 23 Analyst Ratings Have To Say About Eli Lilly and CoMay 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Axonics Modulation Technologies (AXNX) and Eli Lilly & Co (LLY)April 30, 2024 | investorplace.comAXNX Stock Earnings: Axonics Misses EPS, Beats Revenue for Q1 2024April 30, 2024 | businesswire.comAxonics Reports First Quarter 2024 Financial ResultsApril 24, 2024 | prnewswire.comBoston Scientific Announces Results for First Quarter 2024April 4, 2024 | reuters.comFTC seeks more information on Boston Scientific's $3.7 bln Axonics dealMarch 22, 2024 | businesswire.comAxonics Stockholders Approve Merger Agreement with Boston ScientificMarch 21, 2024 | businesswire.comAxonics Provides Update on Inter Partes Review ProceedingsMarch 14, 2024 | businesswire.comAxonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation SystemMarch 1, 2024 | finance.yahoo.comAxonics Full Year 2023 Earnings: EPS Beats ExpectationsFebruary 29, 2024 | marketwatch.comAxonics Pushes Back Against Patent Dispute Alleged by MedtronicFebruary 29, 2024 | businesswire.comAxonics Responds to ITC Action by MedtronicFebruary 29, 2024 | markets.businessinsider.comBeyond The Numbers: 7 Analysts Discuss Axonics StockFebruary 28, 2024 | finance.yahoo.comAxonics Inc (AXNX) Reports Robust Revenue Growth and Margin Expansion in Q4 and FY 2023February 27, 2024 | businesswire.comAXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNXFebruary 3, 2024 | finance.yahoo.comInsider Sell: Chief Medical Officer Karen Noblett Sells 11,288 Shares of Axonics Inc (AXNX)January 17, 2024 | finance.yahoo.comAre Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?January 16, 2024 | realmoney.thestreet.comAxonics just downgraded at Morgan Stanley, here's whyJanuary 16, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Axonics Modulation Technologies (AXNX) and Siemens Healthineers AG (OtherSEMHF)January 12, 2024 | realmoney.thestreet.comAxonics just downgraded at Truist, here's whyJanuary 12, 2024 | realmoney.thestreet.comAxonics just downgraded at CL King, here's whyJanuary 11, 2024 | realmoney.thestreet.comAxonics just downgraded at Leerink, here's whyJanuary 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Axonics Amid Strategic Acquisition by Boston ScientificSee More Headlines Receive AXNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today5/13/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:AXNX CUSIPN/A CIK1603756 Webwww.axonics.com Phone(949) 396-6322Fax949-396-6321Employees797Year FoundedN/APrice Target and Rating Average Stock Price Target$70.73 High Stock Price Target$75.00 Low Stock Price Target$63.00 Potential Upside/Downside+5.0%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E Ratio249.41 P/E GrowthN/ANet Income$-6,090,000.00 Net Margins-4.12% Pretax Margin-3.60% Return on Equity-2.58% Return on Assets-2.32% Debt Debt-to-Equity RatioN/A Current Ratio9.96 Quick Ratio8.04 Sales & Book Value Annual Sales$366.38 million Price / Sales9.38 Cash Flow$0.13 per share Price / Cash Flow533.85 Book Value$12.59 per share Price / Book5.35Miscellaneous Outstanding Shares51,020,000Free Float50,074,000Market Cap$3.44 billion OptionableOptionable Beta0.60 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Raymond W. Cohen (Age 65)CEO & Director Comp: $1.71MMr. Rinda K. Sama (Age 45)Chief Operating Officer Comp: $902.83kDr. John Woock Ph.D. (Age 41)Executive VP, Chief Marketing & Strategy Officer Comp: $902.83kMr. Alfred J. Ford Jr. (Age 53)Chief Commercial Officer Comp: $902.96kMs. Kari KeeseChief Financial OfficerMr. Guangqiang Jiang Ph.D. (Age 50)Chief Technology Officer Mr. Neil BhalodkarVice President of Investor RelationsMr. Aaron PettitGeneral Counsel & Chief Compliance OfficerMr. Michael V. Williamson Esq. (Age 52)J.D., Senior VP, General & IP Counsel Dr. Karen L. Noblett M.A.S. (Age 61)M.D., Chief Medical Officer Comp: $651.4kMore ExecutivesKey CompetitorsiRhythm TechnologiesNASDAQ:IRTCCantel MedicalNYSE:CMDPROCEPT BioRoboticsNASDAQ:PRCTTandem Diabetes CareNASDAQ:TNDMInari MedicalNASDAQ:NARIView All CompetitorsInsiders & InstitutionsChamplain Investment Partners LLCSold 1,023,225 shares on 5/13/2024Ownership: 1.752%Ameritas Investment Partners Inc.Sold 188 shares on 5/13/2024Ownership: 0.010%Edgestream Partners L.P.Bought 8,767 shares on 5/11/2024Ownership: 0.017%Covestor LtdSold 244 shares on 5/11/2024Ownership: 0.006%Vanguard Group Inc.Sold 218,972 shares on 5/10/2024Ownership: 9.883%View All Insider TransactionsView All Institutional Transactions AXNX Stock Analysis - Frequently Asked Questions Should I buy or sell Axonics stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AXNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXNX, but not buy additional shares or sell existing shares. View AXNX analyst ratings or view top-rated stocks. What is Axonics' stock price target for 2024? 13 analysts have issued 12 month target prices for Axonics' shares. Their AXNX share price targets range from $63.00 to $75.00. On average, they expect the company's stock price to reach $70.73 in the next twelve months. This suggests a possible upside of 5.0% from the stock's current price. View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts. How have AXNX shares performed in 2024? Axonics' stock was trading at $62.23 at the start of the year. Since then, AXNX stock has increased by 8.2% and is now trading at $67.33. View the best growth stocks for 2024 here. When is Axonics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our AXNX earnings forecast. How were Axonics' earnings last quarter? Axonics, Inc. (NASDAQ:AXNX) issued its quarterly earnings results on Tuesday, April, 30th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.32. The business had revenue of $91.41 million for the quarter, compared to analyst estimates of $89.79 million. Axonics had a negative net margin of 4.12% and a negative trailing twelve-month return on equity of 2.58%. The firm's revenue was up 29.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.19) EPS. What ETFs hold Axonics' stock? ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust Merger Arbitrage ETF (MARB), AltShares Merger Arbitrage ETF (ARB), ProShares Merger ETF (MRGR), AltShares Event-Driven ET (EVNT), IQ Merger Arbitrage ETF (MNA), Fidelity Digital Health ETF (FDHT) and SPDR S&P Health Care Equipment ETF (XHE). What is Raymond W. Cohen's approval rating as Axonics' CEO? 20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend. What other stocks do shareholders of Axonics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT). When did Axonics IPO? Axonics (AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers. Who are Axonics' major shareholders? Axonics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.88%), Champlain Investment Partners LLC (1.75%), Tokio Marine Asset Management Co. Ltd. (0.47%), Picton Mahoney Asset Management (0.39%), Peregrine Capital Management LLC (0.25%) and Swiss National Bank (0.20%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Kari Leigh Keese, Raymond W Cohen, Raymond W Cohen and Rinda Sama. View institutional ownership trends. How do I buy shares of Axonics? Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AXNX) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axonics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
